Fact CheckerSign in

NCT06643728Active, not recruitingPhase 2

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight Without Type 2 Diabetes

Source: ClinicalTrials.gov · Last updated 26 May 2026

Brief summary (registry, in English)

The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.

Status (registry)
Active, not recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
252 (actual)
First submitted
14 Oct 2024
Start date
21 Oct 2024
Primary completion date
16 Jan 2026
Lead sponsor
Eli Lilly and Company
NCT number
NCT06643728

What you commit to

  • Study type: Interventional · Phase 2
  • Participants enrolled: 252
  • From 21 Oct 2024 to the primary completion date, 16 Jan 2026
  • 12 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Have a prior or planned surgical treatment for obesity
  • Have Type 1 Diabetes, latent autoimmune diabetes, been diagnosed with any form of diabetes mellitus except for a prior diagnosis of gestational diabetes mellitus, or history of ketoacidosis or hyperosmolar coma
  • Have any of the following cardiovascular conditions within 3 months prior to screening:
    • acute myocardial infarction
    • cerebrovascular accident (stroke)
    • unstable angina, or
    • hospitalization due to congestive heart failure
  • Currently taking or have taken medications that may cause significant weight gain or promote weight loss within 3 months prior to screening

Other illness

  • Have poorly controlled hypertension
  • Have ongoing or a history of frequent intermittent or chronic tachyarrhythmia syndromes
  • Have ongoing or a history of bradyarrhythmias other than sinus bradycardia
  • Have a history of New York Heart Association (NYHA) Functional Classification III or IV congestive heart failure
  • Have a history of symptomatic gallbladder disease within the past 2 years
  • Have signs and symptoms of any liver disease
  • Have a disease or condition known to cause gastrointestinal malabsorption or a known clinically significant gastric emptying abnormality
  • Have a history of acute or chronic pancreatitis
  • Have renal impairment, measured as estimated glomerular filtration rate \<30 mL/minute/1.73 m2

Lab values

  • Have at least one laboratory value suggestive of diabetes during screening
  • Use of metformin, or any other glucose-lowering medications

Who the study is looking for

  • Have a BMI of
    • ≥30 kilograms per square meter (kg/m2) or
    • ≥27 kg/m2 and \<30 kg/m2, with at least one of the following weight-related comorbidities:
    • Hypertension
    • Dyslipidemia
    • Cardiovascular disease
    • Obstructive sleep apnea
  • Have had a stable body weight for the 3 months prior to randomization (\<5% body weight gain and/or loss)

Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (12)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Pinnacle Research Group, LLC
Coordinator of this site? Confirm its status
AnnistonUnited StatesUnknown status
Central Research Associates
Coordinator of this site? Confirm its status
BirminghamUnited StatesUnknown status
Great Lakes Clinical Trials - Ravenswood
Coordinator of this site? Confirm its status
ChicagoUnited StatesUnknown status
East-West Medical Research Institute
Coordinator of this site? Confirm its status
HonoluluUnited StatesUnknown status
Clinical Neuroscience Solutions, Inc. dba CNS Healthcare
Coordinator of this site? Confirm its status
JacksonvilleUnited StatesUnknown status
Altus Research
Coordinator of this site? Confirm its status
Lake WorthUnited StatesUnknown status
Suncoast Research Group
Coordinator of this site? Confirm its status
MiamiUnited StatesUnknown status
Keystone Clinical Studies
Coordinator of this site? Confirm its status
Plymouth MeetingUnited StatesUnknown status
Eastside Research Associates
Coordinator of this site? Confirm its status
RedmondUnited StatesUnknown status
Rainier Clinical Research Center
Coordinator of this site? Confirm its status
RentonUnited StatesUnknown status
SKY Integrative Medical Center/SKYCRNG
Coordinator of this site? Confirm its status
RidgelandUnited StatesUnknown status
Diablo Clinical Research, Inc.
Coordinator of this site? Confirm its status
Walnut CreekUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.